Suchergebnisse - "Kunimasa, Kei"

PubPharm (8)

1

Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib

enthalten in: Cancer genetics | 2021

von Kunimasa, K. | Nishino, K. | Kukita, Y. | +11

2

Is Osimertinib-Induced Cardiotoxicity Really Harmless?

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Kunimasa, K.

CommentOn: J Clin Oncol. 2021 Feb 1;39(4):328-337. - PMID 33356419

3

A reply to "Cardiac dysfunction due to Osimertinib"

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Kunimasa, K.

CommentOn: Lung Cancer. 2021 Mar;153:186-192. - PMID 33277055

4

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Kunimasa, K. | Oka, T. | Hara, S. | +15

CommentIn: Lung Cancer. 2021 Mar;153:193-194. - PMID 33303241

5

Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab

enthalten in: Investigational new drugs | 2021

von Tamiya, M. | Kunimasa, K. | Nishino, K. | +8

6

Dermatopathic Lymphadenopathy Mimicking Disease Progression During Osimertinib Treatment

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Kunimasa, K. | Honma, K. | Matsumoto, M. | +2

7

Which Is Better EGFR-TKI Followed by Osimertinib : Afatinib or Gefitinib/Erlotinib?

enthalten in: Anticancer research | 2019

von Tamiya, M. | Tamiya, A. | Suzuki, H. | +12

8

Erlotinib Is Effective for Leptomeningeal Carcinomatosis due to Disease Flare after Osimertinib Treatment Failure

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2017

von Kunimasa, K. | Mimura, C. | Kotani, Y.

1
[1]